Engraftment and transplantation outcomes (acute GVHD, chronic GVHD, NRM, relapse, PFS, and OS), with univariate impact of transplantation group
. | No. evaluated . | Standard myeloablative conditioning . | No. evaluated . | Reduced-intensity conditioning . | P . |
|---|---|---|---|---|---|
| Hematologic reconstitution and engraftment | 621 | 215 | |||
| No hematologic recovery | 621 | 25 (4) | 215 | 12 (5.6) | .3 |
| Not evaluable (death < day +15) | 621 | 11 (1.8) | 215 | 5 (2.3) | |
| Primary graft failure | 610 | 14 (2.8) | 210 | 7 (3.2) | |
| Secondary graft failure | 599 | 4 (0.6) | 203 | 4 (1.9) | |
| Stable engraftment | 621 | 581 (93.6) | 215 | 194 (90.2) | |
| D to more than 0.5 × 109/L neutrophils (range) | 599 | 16 (0-90) | 203 | 14 (1-59) | .001 |
| D to more than 50 × 109/L platelets (range) | 599 | 23 (5-90) | 203 | 16 (0-90) | < .001 |
| GVHD | |||||
| Acute GVHD, any grade (% of all cases) | 621 | 362 (58) | 215 | 92 (43) | < .001* |
| No | 259 (42) | 123 (57) | |||
| Grade I | 148 (27) | 39 (20) | |||
| Grade II | 127 (23) | 22 (11) | |||
| Grade III | 58 (11) | 15 (7) | |||
| Grade IV | 29 (5) | 16 (8) | |||
| D onset acute GVHD, median (range) | 15 (1-31) | 13 (1-31) | |||
| Chronic GVHD (%) | 400 | 132 | .15* | ||
| No | 190 (48) | 73 (55) | |||
| Limited | 109 (27) | 31 (24) | |||
| Extensive | 101 (25) | 28 (21) | |||
| NRM (cumulative incidence, 95% CI)† | 621 | 215 | |||
| 3 mo | 0.20 (0.17-0.23) | 0.15 (0.11-0.21) | |||
| 1 y | 0.28 (0.25-0.32) | 0.20 (0.15-0.26) | .04 | ||
| 3 y | 0.32 (0.28-0.36) | 0.22 (0.17-0.28) | |||
| Disease progression/relapse (cumulative incidence, 95% CI)‡ | 621 | 215 | |||
| 3 mo | 0.08 (0.06-0.10) | 0.14 (0.11-0.20) | |||
| 1 y | 0.22 (0.19-0.25) | 0.35 (0.30-0.43) | < .01 | ||
| 3 y | 0.27 (0.24-0.31) | 0.45 (0.38-0.53) | |||
| Progression-free survival (cumulative incidence, 95% CI)§ | 621 | 215 | |||
| 3 mo | 0.72 (0.74-0.80) | 0.76 (0.69-0.81) | |||
| 1 y | 0.50 (0.46-0.54) | 0.45 (0.38-0.52) | .1 | ||
| 3 y | 0.41 (0.37-0.45) | 0.33 (0.27-0.40) | |||
| Overall survival (cumulative incidence, 95% CI)§ | 621 | 215 | |||
| 3 mo | 0.82 (0.79-0.85) | 0.84 (0.79-0.89) | |||
| 1 y | 0.58 (0.54-0.62) | 0.57 (0.49-0.63) | .7 | ||
| 3 y | 0.45 (0.41-0.49) | 0.41 (0.35-0.47) |
. | No. evaluated . | Standard myeloablative conditioning . | No. evaluated . | Reduced-intensity conditioning . | P . |
|---|---|---|---|---|---|
| Hematologic reconstitution and engraftment | 621 | 215 | |||
| No hematologic recovery | 621 | 25 (4) | 215 | 12 (5.6) | .3 |
| Not evaluable (death < day +15) | 621 | 11 (1.8) | 215 | 5 (2.3) | |
| Primary graft failure | 610 | 14 (2.8) | 210 | 7 (3.2) | |
| Secondary graft failure | 599 | 4 (0.6) | 203 | 4 (1.9) | |
| Stable engraftment | 621 | 581 (93.6) | 215 | 194 (90.2) | |
| D to more than 0.5 × 109/L neutrophils (range) | 599 | 16 (0-90) | 203 | 14 (1-59) | .001 |
| D to more than 50 × 109/L platelets (range) | 599 | 23 (5-90) | 203 | 16 (0-90) | < .001 |
| GVHD | |||||
| Acute GVHD, any grade (% of all cases) | 621 | 362 (58) | 215 | 92 (43) | < .001* |
| No | 259 (42) | 123 (57) | |||
| Grade I | 148 (27) | 39 (20) | |||
| Grade II | 127 (23) | 22 (11) | |||
| Grade III | 58 (11) | 15 (7) | |||
| Grade IV | 29 (5) | 16 (8) | |||
| D onset acute GVHD, median (range) | 15 (1-31) | 13 (1-31) | |||
| Chronic GVHD (%) | 400 | 132 | .15* | ||
| No | 190 (48) | 73 (55) | |||
| Limited | 109 (27) | 31 (24) | |||
| Extensive | 101 (25) | 28 (21) | |||
| NRM (cumulative incidence, 95% CI)† | 621 | 215 | |||
| 3 mo | 0.20 (0.17-0.23) | 0.15 (0.11-0.21) | |||
| 1 y | 0.28 (0.25-0.32) | 0.20 (0.15-0.26) | .04 | ||
| 3 y | 0.32 (0.28-0.36) | 0.22 (0.17-0.28) | |||
| Disease progression/relapse (cumulative incidence, 95% CI)‡ | 621 | 215 | |||
| 3 mo | 0.08 (0.06-0.10) | 0.14 (0.11-0.20) | |||
| 1 y | 0.22 (0.19-0.25) | 0.35 (0.30-0.43) | < .01 | ||
| 3 y | 0.27 (0.24-0.31) | 0.45 (0.38-0.53) | |||
| Progression-free survival (cumulative incidence, 95% CI)§ | 621 | 215 | |||
| 3 mo | 0.72 (0.74-0.80) | 0.76 (0.69-0.81) | |||
| 1 y | 0.50 (0.46-0.54) | 0.45 (0.38-0.52) | .1 | ||
| 3 y | 0.41 (0.37-0.45) | 0.33 (0.27-0.40) | |||
| Overall survival (cumulative incidence, 95% CI)§ | 621 | 215 | |||
| 3 mo | 0.82 (0.79-0.85) | 0.84 (0.79-0.89) | |||
| 1 y | 0.58 (0.54-0.62) | 0.57 (0.49-0.63) | .7 | ||
| 3 y | 0.45 (0.41-0.49) | 0.41 (0.35-0.47) |
Test for linear association in a 2*k table, where k was the number of treatment groups compared.
Cumulative incidence with disease progression as competing risk; univariate likelihood ratio test from Cox model = log-rank from Kaplan-Meier.
Cumulative incidence with NRM as competing risk; univariate likelihood ratio test from Cox model = log-rank from Kaplan-Meier.
(1 — sum of NRM and relapse incidence) by definition; identical to Kaplan-Meier estimate; log-rank test.